

Conference Highlights featuring ACTC Collaborators

This itinerary lists some of the sessions and posters where ACTC members are either presenting or have co-authored the presentation. We hope this highlights and provides insight into some of the work being done by ACTC members and collaborators.

Sessions are listed in Pacific Standard Time (North America).

Schedule is current at the time of posting. Titles are listed as submitted.

Sessions featuring ACTC Collaborators as Presenters / Co-Authors

Date and Time	Session Information
Tuesday, Nov 29 4:00pm	<p>Opening Ceremony Mike Weiner, <i>UCSF</i>; Jacques Touchon, <i>Montpellier University</i>; Paul Aisen, <i>USC ATRI</i>; Bruno Vellas, <i>Toulouse University</i></p> <p>CTAD Lifetime Achievement Award Alzheimer's Disease Therapeutic Research Presented to Reisa Sperling and Keith Johnson</p>
Tuesday, Nov 29 4:30pm	<p>Keynote 1 – Targeting Immuno-Metabolic Pathways in Alzheimer's Disease: Novel Mechanisms and Therapeutic Opportunities Suzanne Craft, <i>Wake Forest University School of Medicine</i></p>
Tuesday, Nov 29 4:50pm	<p>Clarity AD: A Phase 3 Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study Evaluating Lecanemab in Early Alzheimer's Disease Michael Irizarry, Christopher van Dyck, Marwan Sabbagh, Randall J. Bateman, Sharon Cohen</p>
Wednesday, Nov 30 10:30am	<p>LB1 – Tau PET associated with plasma p-tau217 and cognitive testing in preclinical AD: Screening data from the AHEAD Study A3 and A45 Trials Keith Johnson, Aaron Schultz, Robert Rissman, Oliver Langford, Emma Thibault, Matthew Myer, Kristopher Kirmess, Michael Irizarry, Jin Zhou, Michael Donohue, Rema Raman, Paul Aisen, Reisa Sperling, AHEAD 3-45 Study Team</p>
Wednesday, Nov 30 10:45am	<p>LB2 – Plasma levels of Abeta42/40 and p-tau217 ratios increase accuracy of amyloid PET prediction in preclinical AD Robert Rissman, Oliver Langford, Michael Donohue, Rema Raman, Sara Abdel-Latif, Matthew Meyer, Kristopher Kirmess, Joel Braunstein, Michael Irizarry, Keith Johnson, Paul Aisen, Reisa Sperling, AHEAD</p>
Wednesday, Nov 30 3:00pm	<p>LB3 – TRAILBLAZER-ALZ 4: Topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer's disease Stephen Salloway, Elly Lee, Michelle Papka, Andrew Pain, Ena Oru, Margaret B. Ferguson, Hong Wang, Michael Case, Ming Lu, Emily C. Collins, Dawn Brooks, John Sims</p>
Wednesday, Nov 30 4:15pm	<p>Topline Results of Phase III GRADUATE I & II Pivotal Trials with Subcutaneous Gantenerumab Randall J. Bateman</p>
Thursday, Dec 1 9:20am	<p>CTAD open discussion: Anti Amyloid Phase 3 results Maria Carrillo, David Knopman, Lefkos Middleton, Ron Petersen</p>

Conference Highlights featuring ACTC Collaborators

Thursday, Dec 1 9:55am	<p>OC12 – Topline Results of EXERT: Can Exercise Protect Against Cognitive Decline in MCI?</p> <p>Carl Cotman, Howard Feldman, Andrea Lacroix, Aladdin Shadyab, Diane Jacobs, David Salmon, Ron Thomas, Shelia Jin, Judy Pa, Jeffrey Katula, Robert Rissman, James Brewer, Youngkyoo Jung, Jing Zhang, Laura Baker</p>
Thursday, Dec 1 10:10am	<p>OC13 – Senolytic Therapy to Modulate the Progression of Alzheimer’s Disease (StoMP-AD) – Pilot Study Results on Central Nervous System Penetrance and Alzheimer’s Disease Biomarkers</p> <p>Mitzi Gonzales, Valentina Garbarino, Tiffany Kautz, Ron Petersen, Tamara Tchkonja, James Kirkland, Suzanne Craft, Sudha Seshadri, Nicolas Musi, Miranda Or</p>
Thursday, Dec 1 11:20am	<p>Tackling Agitation in Alzheimer’s Dementia: Brexpiprazole phase III trial results</p> <p>Panel discussion: Mary Sano, Bruno Vellas, Clive Ballard, Alireza Atri</p>
Thursday, Dec 1 12:15pm	<p>LB7 – ALZ-NET: Using Real World Evidence to Define the Future of Alzheimer’s Treatment and Care</p> <p>Maria Carillo, Gil Rabinovici, Michael Rafii</p>
Thursday, Dec 1 1:45pm	<p>OC17 – Amyloid and Tau PET positive cognitively unimpaired individuals: Destined to decline?</p> <p>Rik Ossenkoppele, Alexa Pichet Binette, Colin Groot, Reisa Sperling, Colin Masters, Weisje Van Der Flier, William Jagust, Ron Petersen, Clifford Jack, Oskar Hansson</p>
Thursday, Dec 1 3:00pm	<p>OC20 – Systematic inflammation and reduced cerebral Aβ clearance triggered by pancreatic amylin</p> <p>Florin Despa, Nirmal Verma, Edric Winford, Peter Nelson, Gregory Jicha, Larry Goldstein, Claire Troakes, Henrik Zterrerberg, John Hardy, Tammarny Lashley</p>
Thursday, Dec 1 3:15pm	<p>OC21 – Prazosin for Agitation in Alzheimer’s Disease: PEACE-AD</p> <p>Elaine Peskind, Murray Raskind, Ronald Thomas, Gregory Jicha, Neela Patel, Aimee Pierce, Sharon Brangman, Mary Sano, Jeffrey Kaye, Miranda Lim, Michael AuOYeung, Michelle Herman, Gabriel Leger, Karen Messer, Howard Feldman</p>
Thursday, Dec 1 4:45pm	<p>LB9 – Higher sensitivity amyloid-PET detection of the earliest focal beta-amyloid accumulation using spatial extent</p> <p>Michelle Farrell, Emma Thibault, J. Alex Becker, Julie Price, Kuang Gong, Aaron Schultz, Michael Properzi, Rachel Buckley, Heidi Jacobs, Bernard Hanseeuw, Reisa Sperling, Keith Johnson</p>
Thursday, Dec 1 5:15pm	<p>LB11 – Cerebrospinal Fluid Biomarker Effects From a Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Alzheimer’s Disease: Results From the PEGASUS Trial</p> <p>Steven E. Arnold, Newman Knowlton, Victoria J. Williams, Jeffrey M. Burns, Monica Crane, Alison J. Mcmanus, Sanjeev N. Vaishnavi, Zoe Arvanitakis, Judith Neugroschl, Karen Bell, Bianca A. Trombetta, Becky C. Carlyle, Pia Kivisakk, Rudolph E. Tanzi, Kent Leslie</p>
Friday, Dec 2 9:20am	<p>LB12 – Use of a Blood-Based Biomarker Test Impacts Clinical Decision Making Among Neurologists Evaluating Patients With Symptoms of Cognitive Impairment</p> <p>Joel Braunstein, Mark Monane, Kim Johnson, B. Joy Snider, Raymond Scott Turner, Jonathan Drake, Daniel Jacobs, Julia Ortega, Joni Henderson, Tim West</p>

Conference Highlights featuring ACTC Collaborators

Friday, Dec 2 1:35pm	OC31 – NVG-291 Phase 1 Results and Phase 1b/2a Study Design in Individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease Daniel Mikol, Judy Toews, Martin Farlow, Bruce Lamb, George Perry, Reisa Sperling, Michael Weiner, Henrik Zetterberg, Jeffrey Cummings
Friday, Dec 2 2:05pm	OC34 – Preliminary evidence for reliability and validity of the Interpersonal Functioning and Daily Activities Questionnaire (IFDAQ) in the A4/LEARN pre-randomization sample Chris Edgar, Rebecca Amariglio, Jordan Barbone, Julie Chandler, Stephen Coons, Michael Donohue, William Lenderking, Reisa Sperling
Friday, Dec 2 3:35pm	LB16 – Phase 1 Preventative Adjuvanted Tau Vaccine, AV-1980R Lon Schneider, Anahit Ghichikyan, Robert Alexander, Henrik Zetterberg, Eric Reiman, Duygu Tosun, Michael Agadjanyan

Conference Highlights featuring ACTC Collaborators

Poster Presentations

Clinical Trials: Methodology – Tuesday, Nov 29 at 4pm to Wednesday, Nov 30 at 6pm

Poster Number	Session Information
P012	Development and Feasibility of a Data-Driven Approach to Preclinical Alzheimer's Disease Clinical Trial Recruitment through Centralized Pre-screening Data Collection Dylan Kirn, Joshua Grill, Paul Aisen, Karin Ernstrom, Seth Gale, Judith Heidebrink, Gregory Jicha, Gustavo Jimenez-Maggiora, Leigh Johnson, Elaine Peskind, Raymond Scott Turner, David Sultzer, Shunran Wang, Reisa Sperling, Rema Raman
P013	Design of Pragmatic Trials for Interventions Targeting Cognitive Decline: Benchmarks from the Cocoa Supplement and Multivitamin Outcomes Study of the Mind (COSMOS-Mind) Mark Espeland, Joann Manson, Steve Rapp, Howard Sesso, Sarah Gaussoin, Sally Shumaker, Laura Baker
P019 LP14A	Development of an abbreviated pre-screening cognitive battery to enhance referral to clinical trials Abigail O'Connell, Eric Fischer, Lauren Latham, Laura Baker, Suzanne Craft
PO20	Long-Term Nicotine Treatment of Mild Cognitive Impairment (The MIND Study): Baseline Characteristics and Study Progress Paul Newhouse, Rema Raman, Andrew Saykin, Julie Dumas, Edward Levin, Kenneth Kellar, Paul Aisen
LP09	The ALZMatch Study: Remote Plasma Acquisition to Pre-screen for Preclinical Alzheimer's Disease Trials Sarah Walter, Rema Raman, Gustavo Jimenez-Maggiora, Robert Rissman, Joshua Grill, Jason Karlawish, Oliver Langford, Stefania Bruschi, Michael Donohue, Kevin Yarasheski, Michael Racke, Reisa Sperling, Jeffrey Cummings, Paul Aisen
LP10	Disease Progression Modeling Identified MRI-based Subtypes with Cognitive Heterogeneity in A4 Study Preclinical Trial Cohort Cameron Shand, Neil Oxtoby, Michael Donohue, Daniel Alexander, Frederick Barkhof
LP12	Recruitment Accelerator for Diversity in Aging Research – Cognitive Loss and Dementia (RADAR-CLD): Perspectives on Registry Recruitment Mary Sano, Jennifer Vasconcellos, Margaret Sewell, Judith Neugroschl, Mari Umpierre, Shehan Chin, Sharon Brangman, Sarah Mcnamara, Nancy Smith, Kathy Royal, Mike Splaine

New Therapies and Clinical Trials – Tuesday, Nov 29 at 4pm to Wednesday, Nov 30 at 6pm

Poster Number	Session Information
P026	CYP46A1 activation by low-dose efavirenz enhances brain cholesterol metabolism in subjects with mild cognitive impairment due to Alzheimer's disease Alan Lerner, Steven Arnold, Erin Maxfield, Aaron Koenig, Maria Toth, Brooke Fortin, Bianca Trombetta, Andrew Pieper, Curtis Tatsuoka, Irina Pikuleva

Conference Highlights featuring ACTC Collaborators

LP19	<p>Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease: clinical proof of concept in Phase 2 HD study supports clinical development in an ongoing Phase 1/2 AD study</p> <p>Terrence Fisher, Elizabeth Evans, Megan Boise, Vikas Mishra, Crystal Mallow, Ernest Smith, John Leonard, Andrew Feigin, Eric Siemers, Elizabeth Sheldon, Raymond Scott Turner, Martin Farlow, Anton Porteinsson, Wendy Bond, Maurice Zauderer</p>
------	--

Clinical Trials Biomarkers including plasma – Thursday, Dec 1 from 8am to 6pm

Poster Number	Session Information
P109	<p>Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer's Disease</p> <p>Charisse N. Winston, Oliver Langford, Natalie Levin, Rema Raman, Kevin Yarasheski, Tim West, Sara Abdel-Latif, Michael Donohue, Akinori Nakamura, Kenji Toba, Colin L. Masters, James Doecke, Reisa Sperling, Paul Aisen, Robert Rissman</p>
P115	<p>Impact of Alzheimer's Disease Biomarker Disclosure to Cognitively Unimpaired Individuals: Experience from a Truncated Randomized Phase 2b/3 Clinical Trial</p> <p>Joshua Grill, Rema Raman, Garrett Miller, Karin Ernstrom, Garrett Miller, Karin Ernstrom, Michael Donohue, Paul Aisen, Reisa Sperling, David Henley, H. Robert Brashear, Gary Romano, Gerald Novak</p>
LP67	<p>Association of circulating brain-enriched microRNAs with demographic and clinical factors in A4 screening plasma samples from cognitively normal individuals</p> <p>Michael Keifer, Kira Sheinerman, Vladimir Tsivinsky, Brittany Martinez, Robert Rissman, Samuil Umansky</p>

Cognitive and Functional Endpoints – Thursday, Dec 1 from 8am to 6pm

Poster Number	Session Information
LP87	<p>Assessing Clinical Meaningful Functional Outcomes in Preclinical Alzheimer's Disease</p> <p>Carla Romano, Gerald Novak, Jiyeon Choi, Shanshan Qin, David Henley, Michael Donohue, Cary Romano, Rema Raman, Rebecca Amariglio, Paul Aisen, Reisa Sperling</p>

Cognitive assessment and clinical trials – Friday, Dec 2 from 8am to 5pm

Poster Number	Session Information
LP91	<p>Sex differences in the association between tau OET and cognition in preclinical AD (A4 Study)</p> <p>Xin Wang, Erin Sundermann, Sarah Banks</p>

Conference Highlights featuring ACTC Collaborators

Digital Health/E-Trials – Friday, Dec 2 from 8am to 5pm

Poster Number	Session Information
P219	Intuition: a brain health study using multimodal digital biomarkers to decipher cognitive profiles of individuals at-risk for Alzheimer’s and related dementias Monroe Butler, Anton Porsteinsson, Sean Kenny, Hansen Lenyoun, Matt Hobbs, Roland Brown, Matt Bianchi, James Williams, Audrey Gabelle, Shibeshih Belachew, Intuition Study Scientific Committee
P220	Cognitive health in underrepresented populations: early learnings from the Intuition brain health study Rhoda Au, Monroe Butler, Hanson Lenyoun, Sean Kenny, Roland Brown, Paramita Saha-Chaudhuri, Matt Bianchi, James Williams, Audrey Gabelle, Shibeshih Belachew, Intuition Study Scientific Committee